M
Marnie Elizaga
Researcher at Fred Hutchinson Cancer Research Center
Publications - 27
Citations - 1094
Marnie Elizaga is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: HIV vaccine & Vaccination. The author has an hindex of 15, co-authored 25 publications receiving 1015 citations. Previous affiliations of Marnie Elizaga include University of Washington & HIV Vaccine Trials Network.
Papers
More filters
Journal ArticleDOI
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
Spyros A. Kalams,Scott D. Parker,Marnie Elizaga,Barbara Metch,Srilatha Edupuganti,John Hural,Stephen C. De Rosa,Donald K. Carter,Kyle Rybczyk,Ian Frank,Jonathan D. Fuchs,Beryl A. Koblin,Denny H. Kim,Patrice Joseph,Michael C. Keefer,Lindsey R. Baden,John H. Eldridge,Jean D. Boyer,Adam Sherwat,Massimo Cardinali,Mary Allen,Michael Pensiero,Christopher C Butler,Amir S. Khan,Jian Yan,Niranjan Y. Sardesai,James G. Kublin,David B. Weiner +27 more
TL;DR: This study illustrates the power of combined DNA approaches to generate impressive immune responses in humans by using electroporation after PV administration to provide immunogenicity superior to that observed in the trial without Electroporation, despite fewer vaccinations.
Journal ArticleDOI
Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Paul A. Goepfert,Marnie Elizaga,Alicia Sato,Li Qin,Massimo Cardinali,Christine M. Hay,John Hural,Stephen C. DeRosa,Olivier D. Defawe,Georgia D. Tomaras,David C. Montefiori,Yongxian Xu,Lilin Lai,Spyros A. Kalams,Lindsey R. Baden,Sharon E. Frey,William A. Blattner,Linda S. Wyatt,Bernard Moss,Harriet L. Robinson +19 more
TL;DR: MVA62 was well tolerated and elicited different patterns of T cell and Ab responses when administered alone or in combination with the JS7 DNA vaccine.
Journal ArticleDOI
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
Spyros A. Kalams,Scott D. Parker,Xia Jin,Marnie Elizaga,Barbara Metch,Maggie Wang,John Hural,Michael David Lubeck,John H. Eldridge,Massimo Cardinali,William A. Blattner,Magda Sobieszczyk,Vinai Suriyanon,Artur Kalichman,David B. Weiner,Lindsey R. Baden +15 more
TL;DR: There were minimal responses to HIV gag DNA alone, and no apparent augmentation with either IL-12 or IL-15 plasmid cytokine adjuvants, despite the promise of DNA vaccines, newer formulations or methods of delivery will be required to increase their immunogenicity.
Journal ArticleDOI
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles
Paul A. Goepfert,Marnie Elizaga,Kelly E. Seaton,Georgia D. Tomaras,David C. Montefiori,Alicia Sato,John Hural,Stephen C. DeRosa,Spyros A. Kalams,M. Juliana McElrath,Michael C. Keefer,Lindsey R. Baden,Javier R. Lama,Jorge Sanchez,Mark J. Mulligan,Susan Buchbinder,Scott M. Hammer,Beryl A. Koblin,Michael Pensiero,Christopher C Butler,Bernard Moss,Harriet L. Robinson +21 more
TL;DR: DDMM and MMM vaccinations with virus-like particle-expressing immunogens elicited durable antibody and T-cell responses and six months after vaccination, the magnitudes of antibodies and T -cell responses had decreased by <3-fold.
Journal ArticleDOI
A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers
Paul Spearman,Michelle Lally,Marnie Elizaga,David C. Montefiori,Georgia D. Tomaras,M. Juliana McElrath,John Hural,Stephen C. De Rosa,Alicia Sato,Yunda Huang,Sharon E. Frey,Paul A. Sato,John J. Donnelly,Susan W. Barnett,Lawrence J. Corey +14 more
TL;DR: Potent neutralization against neutralization-sensitive strains of HIV is achievable in humans through a DNA prime, recombinant oligomeric Env protein boost regimen, and Eliciting substantial breadth of neutralization remains an elusive goal.